ERBB2 and breast carcinoma: In the present study, we summarized the genomic data that influence the efficacy of HER2 ADCs in metastatic breast cancer and provided crucial insights into the genomic factors that influence responses to HER2 ADCs, highlighting the potential of precision medicine in this field.